ASCO 2026 Data Demonstrate Long-term Survival Benefit of Plinabulin/Docetaxel and Pembrolizumab in Metastatic NSCLC Following Progression on ...
On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic ...
Parabilis Medicines is rated a Buy; it leverages rare, genetically simple tumors to validate its Helicon platform. Read more ...
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its ...
Seattle biotech InduPro has raised $77 million and dosed its first patient in a Phase 1 trial of an experimental cancer drug, ...
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset ...
A prime example unfolded when Royalty Pharma plc (NASDAQ:RPRX) acquired a portion of Neurimmune’s royalty interest in ...
Roche's Q2 results show 5% revenue growth, margin upside and key pipeline catalysts ahead. Click to read my analysis.
At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals Q2 2026 Investor Update Conference Call. [Operator Instructions] I would like to now turn the call over to Chris Stamm, ...
JW Pharmaceutical (KRX:001060) announced that the multinational Phase 3 clinical trial of its gout treatment candidate ...
It's a twice-a-year injection that is remarkably effective in preventing an HIV infection. Distribution is starting. But ...